Unicycive Therapeutics Inc
UNCY
NASDAQ
Biotechnology
$5.51
USD
+0.11 (+2.04%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $137.24M
Volume 767.7K
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The company is headquartered in Los Altos, California and currently employs 21 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
CEO
Dr. Shalabh Gupta
HQ
Los Altos, CALIFORNIA, US
Founded
2021
Employees
21
Key Metrics
2 metrics our research team weighs before forming a view on UNCY.
Based on Quantli research · SEC filings · as of Q2 2026
METRIC
VALUE
CHANGE
TREND (3Y)
ROE (TTM)
-66.1%
+125.6 pp
Free Cash Flow (TTM)
$-27.85M
—
Financial Snapshot
Revenue
$0
— YoY
Gross Margin
—
— YoY
Net Income
$-35.22M
-11.8%
YoY
Operating Cash Flow
$-27.84M
+16.0%
YoY
Key Statistics
Open
$5.42
Previous Close
$5.40
Day Range
$5.40 - $5.65
52 Week Range
$3.48 - $8.74
Volume
767.7K
Average Volume (10 Days)
730.0K
Dividend Yield
—
Valuation Measurement
Market Cap
$137.24M
P/E Ratio (TTM)
—
Price / Book
2.58
Financial Highlights
Return on Assets
-48.9%
Return on Equity
-66.1%
Revenue (TTM)
$0
Net Income (TTM)
$-35.22M
Diluted EPS (TTM)
-$1.64
Total Cash (MRQ)
$44.19M
Levered FCF (TTM)
$-27.85M
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
Similar Stocks
CNTB
Connect Biopharma Holdings Ltd
$2.55
▲ +0.4%
CUE
Cue Biopharma Inc
$34.20
▲ +10.0%
HURA
TuHURA Biosciences Inc
$2.47
▲ +7.4%
EQ
Equillium Inc
$2.36
▲ +17.4%
OTLK
Outlook Therapeutics Inc
$0.7600
▼ -14.9%
CNTN
Canton Strategic Holdings Inc
$2.02
▲ +2.5%
CRBU
Caribou Biosciences Inc
$1.58
▼ -1.9%
SPRB
Spruce Biosciences, Inc
$52.64
▲ +5.8%
OKUR
Onkure Therapeutics Inc
$3.99
▲ +2.3%
IMDX
Insight Molecular Diagnostics Inc
$4.32
▲ +16.4%
Earnings Calendar
Next Earnings
Estimated Q2 Release
Aug 17
Est. EPS
Adjusted consensus estimate
-$0.34
Analyst Consensus
Based on 4 analyst ratings
Avg Target: $25.00
(+353.7% upside)
High: $50.00 · Low: $13.00
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%